CTX130

Welcome to the Brand page for “CTX130”, which is offered here for Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer;gene editing, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, pharmaceutical research and development;.

Its status is currently believed to be active. Its class is unavailable. “CTX130” is believed to be currently owned by “CRISPR Therapeutics AG”.